Scimitar Equity Blog

Positive data from a number of new pre-clinical studies using its CTX stem cell line for stroke was announced (4/29/10).  The new data include the results from a recent pre-clinical efficacy study using ReNeuron’s CTX stem cell line, which RENE is taking forward into the clinic as a (ReN001) therapy for disabled stroke patients. This finding supports  the mode of administration to be used in RENE’s UK Phase I clinical trial with ReN001 in disabled stroke patients with direct injection of the cells close to the area of stroke brain damage. 

• This new efficacy study (again) showed significantly improved outcomes in the key behavioral tests in the CTX cell-treated group in a validated rodent model of stroke damage,
• The results replicate the findings of previous efficacy studies with the CTX cell line, confirming its efficacy in models of stable state stroke damage, 
• This study also tested the effect of the cells when implanted away from the site of stroke damage; however, no equivalent functional improvements were seen,
• The functional effects of the CTX cells on stable stroke deficits therefore appear to be specific to the site of implantation.

In another of the pre-clinical studies to be presented,  CTX stem cells were successfully implanted into the site of stroke damage on a growth factor-secreting micro-particle scaffold, providing structural support within the lesion to promote cell survival and consequent tissue regeneration from the transplanted cells.  In a further study, CTX cells were successfully labeled with a contrast agent developed by Celsense offering the potential for the cells to be detected and tracked by magnetic resonance imaging (MRI) once implanted but without adversely affecting the viability of the cells. 

Also, a major shareholder, David Royds has upped his stake in the company with an increase of 7.9 M shares. Royds now holds 24.15 M shares, which represents 5.517% of ReNeuron’s issued share capital.